Evans, Chair of Arthurian Life Sciences, has purchased 24m shares (worth £600,000) in ReNeuron, which will shortly move from Surrey to Wales.
ReNeuron has raised a total of £33m investment to help position it as a global leader in stem cell development.
This includes £7.8m through a grant package from the Welsh Government to establish a cell manufacturing and R&D facility in South Wales.
The Wales Life Sciences Investment Fund, managed by Arthurian Life Sciences, will invest £5m in the company.
Sir Chris Evans said: “I have been intimately involved with the creation and development of this company for the last 13 years. I have always been convinced of the compelling scientific case behind it and this continues to be confirmed by the results of the clinical trials to date.
“Now that we have secured this substantial financing for the company through to the critical clinical endpoints for all the product pipelines I am totally confident that we can ultimately drive this company to secure highly profitable partnerships or a substantive trade sale within the next three to four years.”
“ReNeuron has always been the outstanding company in the stem cell field, with its novel therapeutic formulations targeting areas of significant unmet or poorly met medical need,” commented Martin Walton, CEO of Excalibur, another of Sir Chris Evans’ companies.
“It has three therapies in development which we believe will ultimately contribute to cures for victims left disabled by stroke, for diabetes sufferers with ischaemia of the legs, and retinal blindness. These will transform the lives of millions of sufferers, and the market for these treatments globally is enormous.”